Primer set, kit and method for detecting UGT1A1 gene polymorphism
By providing specific primer sets and fluorescence quantitative PCR, the problem of incomplete typing and cumbersome operation of detecting polymorphisms of UGT1A1 gene is solved, and rapid and accurate genotype determination is achieved, which is suitable for clinical laboratories.
Patent Information
- Application Number
- CN202410119240.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-01-29
AI Technical Summary
In the prior art, the problem of incomplete typing, cumbersome operation and long time detection of UGT1A1 gene polymorphism products.
A detection method including a specific primer set is provided, using fluorescence quantitative PCR method (PAP-qPCR) to detect UGT1A1 gene polymorphisms, and to achieve rapid and accurate genotype determination through the pyrolytic deactivation mechanism, simplifying the operation process.
It realizes faster and simpler UGT1A1 gene polymorphism detection, improves the accuracy and efficiency of the detection, and is suitable for clinical laboratory promotion.
Smart Images

Figure CN117904281B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a primer set, a kit and a method for detecting UGT1A1 gene polymorphism, and belongs to the technical field of biological detection and analysis. Background Art
[0002] Hereditary unconjugated hyperbilirubinemia, including Crigler-Najjar syndrome type I (CN-1), Crigler-Najjar syndrome type II (CN-2), and Gilbert syndrome (GS), are all caused by mutations in the bilirubin uridine diphosphate glucuronyltransferase 1A1 (UDP-GT enzyme) gene. The gene encoding the UDP-GT enzyme, UGT1A1, is located at 2q37.1. Its DNA includes 13,027 bases, its mRNA consists of 2,361 bases, and its protein is encoded by 533 amino acids. In bilirubin metabolism, unconjugated bilirubin (IBil) is metabolized to conjugated bilirubin (DBil) by UGT1A1, which is the main rate-limiting metabolic enzyme in this reaction. When the UGT1A1 gene mutation leads to reduced or lost enzyme activity, unconjugated bilirubin cannot be converted into conjugated bilirubin and accumulates in the body.
[0003] In the normal population, about 6 to 12% of people have UDP-GT enzyme deficiency, and their biochemical indicators are elevated indirect bilirubin and normal liver function indicators such as ALT. Patients show fatigue and lack of energy, and the causes of the disease include infection (such as colds or flu), fasting or low-calorie diets, dehydration, strenuous exercise, stress, and female menstruation. UGT1A1 gene polymorphism is the molecular genetic basis of Gilbert syndrome and can be used to assist in the diagnosis of Gilbert syndrome.
[0004] UGT1A1 gene mutations include insertions, deletions, and single nucleotide polymorphisms, which lead to large individual differences in sequences. At present, 160 mutants of this gene have been found. According to the international common naming method, the wild type is marked as UGT1A1*1, and the mutants are marked as *2, *3, *4, *5, etc. At present, there are three main forms of genetic polymorphism of UGT1A1 gene: ① mistranslation mutations in the exon region, such as: UGT1A1*6 (c.211G>A, G71R), UGT1A1*27 (c.686C>A, P229Q), UGT1A1*63 (c.1091C>T, P364L), UGT1A1*7 (c.1456T>G, Y486D), etc., and G>A (G71R) at nucleotide 211 position on exon 1 is the most common. ② Promoter TATA box TA insertion mutation, which is manifested as the insertion of a dinucleotide (TA) into the TATA box about 25-35 bp upstream of the UGT1A1 gene promoter, causing the normal wild-type A[TA]6TAA to mutate into polymorphic forms such as A[TA]7TAA or A[TA]8TAA. ③ Phenobarbital-responsive enhancer module (PBREM) region, c.-3279T>G, this mutation has a strong linkage phenomenon with A[TA]7TAA. In recent years, combining indirect bilirubin levels with genetic test results and genetic laws has become an important means of diagnosing Gilbert syndrome.
[0005] Patent publication number CN112592970A discloses a Gilbert syndrome UGT1A1 multi-site mutation detection kit, which includes primer pairs and probes for non-labeled probe HRM detection of four mutation sites of UGT1A1, p.G71R, p.P229Q, p.Y486D and A[TA]7TAA. This method places very high requirements on the temperature resolution and temperature uniformity of the instrument. Summary of the invention
[0006] The purpose of the present invention is to solve the problems in the prior art of detecting UGT1A1 gene polymorphism product typing, which are incomplete in types, complicated in operation and time-consuming. To achieve the above purpose, the present invention provides a primer set for detecting UGT1A1 gene polymorphism, comprising:
[0007] Primers for detecting UGT1A1*6 gene, containing:
[0008] c.211A typing with upstream primer U-6A-F1: 5'-CGTTGTACATCAGAGACa-3',
[0009] c.211G typing with upstream primer U-6G-F1: 5'-CGTTGTACATCAGAGACg-3',
[0010] c.211G / A typing common downstream primer UGT*6-R1: 5'-CCGAGACTAACAAAAGACTCT-3';
[0011] Primers for detecting UGT1A1*28 gene, containing:
[0012] c.-53TA6 / TA7 typing common upstream primer U-286-F1: 5'-CCTGCTACCTTTGTGGACTG-3',
[0013] The downstream primer U-7R-R21 used for c.-53TA7 typing was 5′-GCCCTCTCCTACTTATATATATATATAaGG-3′, and the downstream primer U-6R-R21 used for c.-53TA6 typing was 5′-GCCCTCTCCTACTTATATATATATATATAaGG-3′;
[0014] Primers for detecting UGT1A1*60 gene, containing:
[0015] c.-3279T typing with upstream primer U-3279T-22F1: 5'-CCAAGGGTAGAGTTCAGTt-3',
[0016] c.-3279G typing with upstream primer U-3279G-22F1: 5'-CCAAGGGTAGAGTTCAGTg-3',
[0017] c.-3279T / G typing common downstream primer U-3279-22R1: 5'-atCAAACTTcCTTTGATGTTCt-3';
[0018] Primers for detecting UGT1A1*27 gene, containing:
[0019] c.686C typing with upstream primer U-P229-F1: 5'-GACGTGGTTTATTCCCc-3',
[0020] c.686A typing with upstream primer U-P229Q-F1: 5'-GACGTGGTTTATTCCCa-3',
[0021] c.686C / A typing common downstream primer U-P229-R2: 5′-agaGGACAGTCACCTCTCTCTGAA-3′;
[0022] Primers for detecting UGT1A1*63 gene, containing:
[0023] c.1091C / T typing shared upstream primer U-P364-F11: 5'-gacACCTAGATGTGTCCAGC-3',
[0024] c.1091C typing with downstream primer U-P364-R1: 5'-AGGCACGGGTCATCGg-3',
[0025] c.1091T typing with downstream primer U-P364L-R102: 5′-AAAGGCACGGGTCATCa-3′;
[0026] Primers for detecting UGT1A1*7 gene, containing:
[0027] c.1456T typing with upstream primer U-Y486-F1: 5'-CCTCACCTGGTACCAGt-3',
[0028] c.1456G typing with upstream primer U-Y486D-F4: 5'-GACCTCAaCTGGTACCAGg-3',
[0029] c.1456T / G typing shared downstream primer U-Y486-R1: 5'-gtttCCAAGAGGAAACCAATCAC-3'.
[0030] Preferably, the 5' end of the primers U-6A-F1, U-6G-F1, U-P229-F1, U-P229Q-F1, U-Y486-F1, U-Y486D-F4, U-7R-R21, U-6R-R21, U-3279T-22F1, U-3279G-22F1, U-P364-R1, and U-P364L-R102 are labeled with a fluorescent reporter group, and the 3' end is labeled with a fluorescent quencher group; preferably, different labeled primers at the same site are labeled with the same marker.
[0031] Preferably, the 5' end is labeled with a fluorescent reporter group including one or more of FAM, Texas Red, ROX, HEX, VIC, NED, and CY5, and the 3' end is labeled with a fluorescent quencher group including one or more of BHQ1, BHQ2, and BHQ3.
[0032] Preferably, the 3' end of the primer is dehydroxylated.
[0033] The present invention also provides a kit for detecting UGT1A1 gene polymorphism, comprising a PCR reaction solution and a GS reaction tube, wherein the GS reaction tube contains a primer set for detecting UGT1A1 gene polymorphism.
[0034] Preferably, the PCR reaction solution includes 0.1-0.2 U / μL Taq enzyme, 1.5-5 mM MgCl2, 20 mM Tris-HCl, 100 mM KCl, 0.05-0.5 mM dNTPs, and 5 mM sodium pyrophosphate.
[0035] Preferably, the concentration of the primer set is 12 pmol / tube.
[0036] The present invention also provides a method for detecting UGT1A1 gene polymorphism, comprising:
[0037] Extracting genomic DNA from the sample to be tested;
[0038] Fluorescence quantitative PCR premix was prepared using a kit for detecting UGT1A1 gene polymorphism;
[0039] Take the prepared fluorescence quantitative PCR premix and add it to the GS reaction tube, put it into the fluorescence quantitative PCR instrument to carry out fluorescence quantitative PCR reaction, detect the fluorescence signal and determine the result.
[0040] Preferably, the fluorescent quantitative PCR premix includes 44 μL of PCR reaction solution, 120-400 ng of sample DNA and water.
[0041] Preferably, the reaction procedure of the fluorescent quantitative PCR is: 95°C, 10 min; 95°C, 10 s, 60°C, 45 s, 5 cycles; 95°C, 10 s, 60°C, 35 s, 40 cycles; 25°C, 10 s
[0042] The beneficial effects achieved by the present invention are:
[0043] 1. The present invention uses a pyrophosphorolysis-activated fluorescent PCR method (PAP-qPCR) to detect UGT1A1 gene polymorphism. The principle of the method is: in the PCR reaction system, inorganic pyrophosphate is added. At this time, when there is no hydroxyl group at the 3' end of the primer, the primer and the template are completely complementary, and inorganic pyrophosphate decomposes the 3' end base of the primer (which can be considered as the reverse reaction of DNA polymerization, and this hydrolysis of the DNA chain requires the presence of template DNA). After the primer removes the first base at the 3' end, a primer that can be used for PCR reaction is formed at the 3' end, that is, the PCR reaction is initiated; the labeled primer is labeled with a 5' fluorescent group-3' quenching group. When pyrophosphorolysis occurs, the quenching group falls off the primer to form a fluorescent signal.
[0044] 2. Compared with the PCR-Sanger sequencing method, the PAP-qPCR detection kit based on the fluorescence PCR instrument provided by the present invention is not only easy to operate, has a short detection time, but also has a timely report response. In addition, PAP-qPCR can more accurately analyze the number of repetitive sequences, has better performance, and has the advantages of fewer operating steps, convenience, and easy standardization, which is suitable for promotion in clinical laboratories. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*6 type site in sample No. 3.
[0046] Figure 2 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*6 type site in sample No. 1.
[0047] Figure 3 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*6 type site of sample No. 13.
[0048] Figure 4 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*28 type site of sample No. 3.
[0049] Figure 5 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*28 type site of sample No. 1.
[0050] Figure 6 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*28 type site of sample No. 6.
[0051] Figure 7 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*60 site of sample No. 7.
[0052] Figure 8 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*60 site of sample No. 1.
[0053] Fig. 9 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*60 site of sample No. 5.
[0054] Fig.10 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*27 type site of sample No. 2.
[0055] Fig.11 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*27 type site of sample No. 3.
[0056] Fig.12 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*63 site of sample No. 1.
[0057] Fig.13 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*63 type site of sample No. 21.
[0058] Fig.14 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*7 type site in sample No. 2.
[0059] Fig.15 This is the fluorescence quantitative PCR amplification curve of the UGT1A1*7 type site of sample No. 26. DETAILED DESCRIPTION
[0060] The present invention will be further described below in conjunction with the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and cannot be used to limit the protection scope of the present invention.
[0061] The present invention uses the PAP-qPCR method to detect UGT1A1 gene polymorphic sites, and the sites to be tested are all Gilbert syndrome-related sites. The relevant information of these sites to be tested is shown in Table 1.
[0062] Table 1 Sites to be tested
[0063]
[0064]
[0065] Example
[0066] A method for detecting UGT1A1 gene polymorphism comprises the following steps:
[0067] (1) Sample DNA extraction
[0068] Oral swab samples were collected from 26 test subjects, and DNA from the samples was extracted using a commercial DNA extraction kit (Beijing Tiangen DNA Extraction Kit, DP322). The specific steps are as follows:
[0069] a) Place the oral swab sample in a 2 mL centrifuge tube, add 400 μL of buffer GA and 20 μL of proteinase K solution, vortex to mix, and place at 56°C for 60 min.
[0070] b) Add 400 μL of buffer GB, vortex to mix, place at 70°C for 10 min, and transfer the solution to a new centrifuge tube.
[0071] c) Add 200 μL of anhydrous ethanol to a new centrifuge tube, shake and mix, add to the adsorption column, centrifuge at 12000 rpm for 30 seconds, and discard the washing liquid in the waste liquid collection tube.
[0072] d) Add 500 μL of buffer GD, centrifuge at 12,000 rpm for 30 s, and discard the washing liquid in the waste liquid collection tube.
[0073] e) Add 600 μL of rinse solution PW, centrifuge at 12000 rpm for 30 s, discard the rinse solution in the waste liquid collection tube, and centrifuge at 12000 rpm for 2 min.
[0074] f) Place the adsorption column in a 1.5 mL centrifuge tube, add 50 μL of elution solution, centrifuge at 12,000 rpm for 2 min to elute the DNA, and collect the solution in a centrifuge tube. The obtained solution is the sample DNA.
[0075] (2) Fluorescence quantitative PCR detection
[0076] A fluorescent quantitative PCR premix was prepared using a kit for detecting UGT1A1 gene polymorphism. The detailed composition of the kit is shown in Table 2, Table 3 and Table 4. Take out the PCR reaction solution in the kit for detecting UGT1A1 gene polymorphism and prepare the premix according to Table 5. Take the reaction tube in the kit for detecting UGT1A1 gene polymorphism, centrifuge for 30 seconds, and pipette 20 μL of the premix into the prepared GS reaction tube in turn. Seal the PCR tube cap and record the sample addition and placement order. Place the PCR reaction tube in the ABI 7500 fluorescent quantitative PCR instrument, run the program as shown in Table 6, and set the fluorescence detection to 60°C in the third step "40 cycles" of the program to detect the fluorescence of FAM and HEX.
[0077] Table 2 Composition of the kit
[0078]
[0079]
[0080] Table 3 Primer composition in GS reaction tube
[0081] Reaction tube number Primers 1 U-6A-F1, UGT*6-R1 2 U-6G-F1, UGT*6-R1 3 U-286-F1, U-7R-R21 4 U-286-F1, U-6R-R21 5 U-3279T-22F1, U-3279-22R1 6 U-3279G-22F1, U-3279-22R1 7 U-P229-F1, U-P229-R2 8 U-P229Q-F1, U-P229-R2 9 U-P364-F11, U-P364-R1 10 U-P364-F11, U-P364L-R102 11 U-Y486-F1, U-Y486-R1 12 U-Y486-F4, U-Y486-R1
[0082] Table 4 Primers
[0083]
[0084]
[0085] Table 5 Composition of premix
[0086]
[0087]
[0088] Table 6 Fluorescence quantitative PCR reaction program
[0089]
[0090] (3) Results analysis
[0091] After the reaction is completed, the results are automatically saved and the amplification curve is analyzed. According to the image after analysis, adjust the Start value and End value of the Baseline (users can adjust it according to actual conditions, the Start value can be set to 3-15, and the End value can be set to 5-20), set the Threshold value (Rn) to the inflection point of the rising fluorescence signal, click Analyze to analyze, and then record the Ct value of each reaction in the Plate window. The amplification curves of some samples are as follows: Figure 1 to Figure 15 shown.
[0092] The genotype of the sample is interpreted according to the difference △Ct between the Ct value of the mutant detection system and the Ct value of the wild-type detection system. If △Ct≤-3, the genotype of the gene locus of the sample is mutant; if -3<ΔCt<3, the genotype of the gene locus of the sample is heterozygous; if △Ct≥3, the genotype of the gene locus of the sample is wild-type. The test data are analyzed based on the result judgment basis in Table 7, and the sample results are shown in Table 8.
[0093] Table 7 Results judgment basis
[0094]
[0095]
[0096] Table 8 Sample test results
[0097]
[0098]
[0099] As can be seen from Table 8, the method of the embodiment was used to detect the UGT1A1 gene polymorphism of 26 samples, among which there were 11 wild-type cases, 13 heterozygous cases, and 2 mutant cases at the UGT1A1*6 site; there were 6 wild-type cases, 9 heterozygous cases, and 11 mutant cases at the UGT1A1*28 site; there were 4 wild-type cases, 15 heterozygous cases, and 7 mutant cases at the UGT1A1*60 site; there were 23 wild-type cases and 3 heterozygous cases at the UGT1A1*27 site; there were 25 wild-type cases and 1 heterozygous case at the UGT1A1*63 site; there were 24 wild-type cases, 1 heterozygous case, and 1 mutant case at the UGT1A1*7 site. The 26 samples in this example were simultaneously genotyped using the Sanger sequencing method, and the results were consistent with the results obtained by the detection method of this example. Therefore, the method of this example has high accuracy, and compared with the Sanger sequencing method, the detection method of this example is simple to operate and saves time.
[0100] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the technical principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A primer set for detecting UGT1A1 gene polymorphism, characterized in that: include: Primers for detecting UGT1A1*6 gene, containing: c.211A typing with upstream primer U-6A-F1: 5'-CGTTGTACATCAGAGACa-3', c.211G typing with upstream primer U-6G-F1: 5'-CGTTGTACATCAGAGACg-3', c.211G / A typing common downstream primer UGT*6-R1: 5'-CCGAGACTAACAAAAGACTCT-3'; Primers for detecting UGT1A1*28 gene, containing: c.-53TA6 / TA7 typing common upstream primer U-286-F1: 5'-CCTGCTACCTTTGTGGACTG-3', c.-53TA7 typing with downstream primer U-7R-R21: 5'-GCCCTCTCCTACTTATATATATATATAaGG-3', c.-53TA6 typing with downstream primer U-6R-R21: 5′-GCCCTCTCCTACTTATATATATATATATAaGG-3′; Primers for detecting UGT1A1*60 gene, containing: c.-3279T typing with upstream primer U-3279T-22F1: 5'-CCAAGGGTAGAGTTCAGTt-3', c.-3279G typing with upstream primer U-3279G-22F1: 5'-CCAAGGGTAGAGTTCAGTg-3', c.-3279T / G typing common downstream primer U-3279-22R1: 5'-atCAAACTTcCTTTGATGTTCt-3'; Primers for detecting UGT1A1*27 gene, containing: c.686C typing with upstream primer U-P229-F1: 5'-GACGTGGTTTATTCCCc-3', c.686A typing with upstream primer U-P229Q-F1: 5'-GACGTGGTTTATTCCCa-3', c.686C / A typing common downstream primer U-P229-R2: 5′-agaGGACAGTCACCTCTCTCTGAA-3′; Primers for detecting UGT1A1*63 gene, containing: c.1091C / T typing common upstream primer U-P364-F11: 5'-gacACCTAGATGTGTCCAGC-3'', c.1091C typing with downstream primer U-P364-R1: 5'-AGGCACGGGTCATCGg-3', c.1091T typing with downstream primer U-P364L-R102: 5′-AAAGGCACGGGTCATCa-3′; Primers for detecting UGT1A1*7 gene, containing: c.1456T typing with upstream primer U-Y486-F1: 5'-CCTCACCTGGTACCAGt-3', c.1456G typing with upstream primer U-Y486D-F4: 5'-GACCTCAaCTGGTACCAGg-3', c.1456T / G typing common downstream primer U-Y486-R1: 5′-gtttCCAAGAGGAAACCAATCAC-3′; The 3' end of the primer is dehydroxylated, and the 5' end of the primers U-6A-F1, U-6G-F1, U-P229-F1, U-P229Q-F1, U-Y486-F1, U-Y486D-F4, U-7R-R21, U-6R-R21, U-3279T-22F1, U-3279G-22F1, U-P364-R1, and U-P364L-R102 are labeled with a fluorescent reporter group, and the 3' end is labeled with a fluorescent quencher group.
2. The primer set for detecting UGT1A1 gene polymorphism according to claim 1, characterized in that: The 5' end is labeled with a fluorescent reporter group including FAM, Texas Red, ROX, HEX, VIC, NED or CY5, and the 3' end is labeled with a fluorescent quencher group including BHQ1, BHQ2 or BHQ3.
3. A kit for detecting UGT1A1 gene polymorphism, characterized in that: It comprises a PCR reaction solution and a GS reaction tube, wherein the GS reaction tube contains the primer set according to any one of claims 1 to 2.
4. The kit for detecting UGT1A1 gene polymorphism according to claim 3, characterized in that: The PCR reaction solution includes 0.1-0.2 U / μL Taq enzyme, 1.5-5 mM MgCl2, 20 mM Tris-HCl, 100 mM KCl, 0.05-0.5 mM dNTPs, and 5 mM sodium pyrophosphate.
5. The kit for detecting UGT1A1 gene polymorphism according to claim 3, characterized in that: The concentration of the primer set was 12 pmol / tube.
